Abstract: A medical breath component analyzer which maintains a data-base profile of a patient over time. The apparatus may be used chronically by a patient so that a baseline status for that patient may be determined. Acute variations from the baseline are identified as clinically significant. The acquired data can be reported to the patient using the device at home and transmitted electronically to a physician or health care provider. The method and apparatus helps a patient modify health related behaviors, particularly weight loss for diabetic patients. A breath component and information on the psychological or emotional state of the patient are correlated, and information is provided to the patient based on the correlation between the breath component and the patient's emotional state. Other physiologic parameter may also be measured, such as a blood component, temperature, cardiovascular condition or pulse rate, a urine component, a physical activity sensor, weight, or body fat composition sensor.

Abstract: The present invention concerns the use of a radioiodinated phenolic compound of the formula wherein: m and n are independently 0, 1, 2 or 3, X is a group that is negatively or positively charged at physiological pH, R, R1, R2 and R3 are independently hydrogen, C1-C4 alkyl, or a carboxyl group, and I* is 123I, 131I or 125I, and its pharmaceutically-acceptable salts. The compound is formulated and used in vivo in an animal in brachytherapy in an implantable catheter. In addition, due to the rapid renal clearance of these compounds, they may be used to study renal function. A process to prepare these compounds is also disclosed.

Abstract: A medical breath component analyzer which maintains a data-base profile of a patient over time. The apparatus may be used chronically by a patient so that a baseline status for that patient may be determined. Acute variations from the baseline are identified as clinically significant. The acquired data can be reported to the patient using the device at home and transmitted electronically to a physician or health care provider. Multiple tests may be provided, ranging from quantitative tests to qualitative tests to quantitative approximations using qualitative devices. A set of tests is selected for a particular patient, and may be customized to the patient's condition. One of the tests may include passing multiple laser beams of differing wavelengths through a breath sample and using pattern recognition to correlate from spectral analysis of all the laser beams.

Abstract: Chelants represented by Formula 1b: ##STR1## are determined to be biodegradable when Distance A is from about 3.8.times.10.sup.-10 to about 4.6.times.10.sup.-10 m, Distance B is from about 5.1.times.10.sup.-10 to about 5.9.times.10.sup.-10 m, and Distance C is from about 4.3 to about 6.7.times.10.sup.-10 m). Compounds meeting these criteria are referred to as compounds of Formula 2.

Abstract: An analytical process for determining the biodegradability of chelants containing a double carboxyl-containing moiety of specified formula, based on the atomic distances between the carboxyl moieties, is disclosed. According to this process the biodegradability of a chelant can be rapidly determined by determining whether the distance between the carboxyl carbon atoms ("Distance A") falls within the range of from about 3.81.times.10.sup.-10 m to about 3.86.times.10.sup.-10 m; the distance between the carboxyl double bonded oxygen atoms ("Distance B") falls within the range from about 5.13.times.10.sup.-10 to about 5.52.times.10.sup.-10 m; and the distance between the carboxyl hydroxy oxygen atoms ("Distance C") falls within a range of from about 5.28.times.10.sup.- m to about 6.09.times.10.sup.-10 m; and whether the lowest unoccupied molecular orbital (LUMO) is on at least one carboxyl carbon atom of the moiety. If all of the above criteria are met, the compound is predicted to be biodegradable.

Abstract: Chelants represented by Formula 1b: ##STR1## are determined to be biodegradable when Distance A is from about 3.8.times.10.sup.-10 to about 4.6.times.10.sup.-10 m, Distance B is from about 5.1.times.10.sup.-10 to about 5.9.times.10.sup.-10 m, and Distance C is from about 4.3 to about 6.7.times.10.sup.-10 m). Compounds meeting these criteria are referred to as compounds of Formula 2.

Abstract: Chelants represented by Formula 1b: ##STR1## are determined to be biodegradable when Distance A is from about 3.8.times.10.sup.-10 to about 4.6.times.10.sup.-10 m, Distance B is from about 5.1.times.10.sup.-10 to about 5.9.times.10.sup.-10 m, and Distance C is from about 4.3 to about 6.7.times.10.sup.-10 m.

Abstract: Polyamino monosuccinic acid chelants are disclosed which have been found to be applicable in photographic processes. The polyamino monosuccinic acids can be used in a method of bleaching or bleach-fixing a silver halide photographic material comprising contacting the photographic material with a bleaching solution containing a metal complex of a polyamino monosuccinic acid as a bleaching agent.

Abstract: A novel liquid nutritional for use as an infant formula for use in the treatment of infantile colic is disclosed. The formula comprises protein, fat, carbohydrates and dietary fiber of a concentration of between 3.1 and 14.1 grams of fiber per liter of formula. Specific preferred protein, fat, carbohydrate and fiber sources are disclosed. Also disclosed is a method of treating infants with colic by feeding an infant the formula made in accordance with the invention. Also disclosed is a method for manufacturing the infant formula of the invention.